4Boedert M. Tau protein and the neruofibrillary pathology of Alzheimer' s disease. Trends in Nenroscience, 1993; 16:460-465.
5Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid β-amyloid (Aβ42) in Alzheimer ' s disease; dirrferences between early-and late-onset Alzheimer disease and stability during thd course of disease. Arch Neural. 1999; 56: 673-680.
6Blennow K, Wallin A, Agron H, et al. Tau protein in cerebrospinal fluid; biochemical diagnostic marker for axonal degeneration in Alzheimer' s disease. Mol Chem Neuropathology,1995; 26: 231-245.
7Andreasen N, Minthon L, Clarberg A, et al.Sensitivity,specificity and stability of CSF-tau in AD in a community-based patient sample. Neurology, 1999; 53: 1488-1494.
8Ishiguro K, Ohno H, Arai H, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer 's disease. Neurosci Lett. 1999; 270: 91-94.
9Arai H,Ishiguro K, Ohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment; a prospective study.Exp Neurol. 2000; 166: 201-203.
10Andreasen, Minthon L, Vanmechelen E, el al. CSF-tau anti CSF-Aβ42 as predictors of development of Alzheimer ' s disease in patients with mild cognitive impairment. Neurosci Lett, 1999; 273: 5-8.
10Hamir A N, Kunkle R A, Miller J M, et al. Second passage of sheep scraple and transmissible mink encephalopathy (TME) agents in raccoons ( Procyon lotor) [ J ]. Vet Pathol, 2005,42 (6) :844 -851.
